Outstanding increase in tumor-to-background ratio over time allows tumor localization by [

Humans Male Positron Emission Tomography Computed Tomography / methods Prostatic Neoplasms / diagnostic imaging Retrospective Studies Aged Zirconium Middle Aged Dipeptides Neoplasm Recurrence, Local / diagnostic imaging Prostate-Specific Antigen / blood Radioisotopes Radiopharmaceuticals Heterocyclic Compounds, 1-Ring Aged, 80 and over
Biochemical recurrence Localization Positron emission tomography/Computed tomography (PET/CT) Prostate cancer Prostate-specific membrane antigen (PSMA) Zirconium-89 (89Zr)

Journal

Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931

Informations de publication

Date de publication:
07 Oct 2024
Historique:
received: 03 07 2024
accepted: 23 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 7 10 2024
Statut: epublish

Résumé

Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 ( Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [ [ retrospective, single center design; infrequent histopathological and imaging verification. This large series provides further evidence that [

Sections du résumé

BACKGROUND BACKGROUND
Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (
METHODS METHODS
Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [
RESULTS RESULTS
[
LIMITATIONS CONCLUSIONS
retrospective, single center design; infrequent histopathological and imaging verification.
CONCLUSION CONCLUSIONS
This large series provides further evidence that [

Identifiants

DOI: 10.1186/s40644-024-00778-5 PMID: 39375762
pubmed: 39375762
doi: 10.1186/s40644-024-00778-5
pii: 10.1186/s40644-024-00778-5
doi:

Substances chimiques

Zirconium C6V6S92N3C
Dipeptides 0
PSMA-617 0
Prostate-Specific Antigen EC 3.4.21.77
Radioisotopes 0
Zirconium-89 NTM296JU95
Radiopharmaceuticals 0
Heterocyclic Compounds, 1-Ring 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132

Informations de copyright

© 2024. The Author(s).

Références

Grunig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [
doi: 10.1007/s00259-021-05424-x pubmed: 34120201 pmcid: 8566387
Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [
doi: 10.1007/s00259-021-05189-3 pubmed: 33543325 pmcid: 8263399
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466–86.
doi: 10.1007/s00259-022-06089-w pubmed: 36604326 pmcid: 10027805
Bagguley D, Ong S, Buteau JP, Koschel S, Dhiantravan N, Hofman MS, et al. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021;17:2225–41.
doi: 10.2217/fon-2020-1293 pubmed: 33724868
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane Antigen Positron Emission Tomography in Advanced prostate Cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane Antigen-avid lesions: a systematic review and Meta-analysis. Eur Urol. 2020;77:403–17.
doi: 10.1016/j.eururo.2019.01.049 pubmed: 30773328
Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with
Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of
Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of
doi: 10.1186/s12885-018-5200-1 pubmed: 30616601 pmcid: 6322287
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.
doi: 10.1007/s00259-016-3573-4 pubmed: 27889802
Prive BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, et al.
doi: 10.1007/s00259-021-05661-0 pubmed: 34932154
Rosar F, Bartholoma M, Maus S, Prive BM, Khreish F, Franssen GM, et al. Zr-PSMA-617 PET/CT may reveal local recurrence of prostate Cancer unidentified by
doi: 10.1097/RLU.0000000000004108
Rosar F, Schaefer-Schuler A, Bartholoma M, Maus S, Petto S, Burgard C, et al. [
doi: 10.1007/s00259-022-05925-3 pubmed: 35930033 pmcid: 9606102
Vazquez SM, Endepols H, Fischer T, Tawadros SG, Hohberg M, Zimmermanns B, et al. Translational Development of a Zr-89-Labeled inhibitor of prostate-specific membrane Antigen for PET imaging in prostate Cancer. Mol Imaging Biol. 2022;24:115–25.
doi: 10.1007/s11307-021-01632-x pubmed: 34370181
Dietlein F, Kobe C, Vazquez SM, Fischer T, Endepols H, Hohberg M, et al. An
doi: 10.2967/jnumed.121.262290 pubmed: 34326129
Rosar F, Burgard C, Linxweiler J, Wagner M, Ezziddin S. Histologically confirmed testicular metastasis revealed by [
Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, et al. Detection efficacy of [
doi: 10.1007/s00259-023-06241-0 pubmed: 37148297 pmcid: 10317886
Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, et al. [
doi: 10.1186/s40644-024-00671-1 pubmed: 38389092 pmcid: 10885487
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al.
doi: 10.1007/s00259-017-3670-z pubmed: 28283702
Yoon JK, Park BN, Ryu EK, An YS, Lee SJ. Current perspectives on
Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco, et al. (A prospective randomized multicentre study of the impact of gallium-68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018;122:783–93.
doi: 10.1111/bju.14374 pubmed: 29726071

Auteurs

Caroline Burgard (C)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. caroline.burgard@uks.eu.
Saarland University, USAAR, Saarbrücken, Germany. caroline.burgard@uks.eu.
ORCID: 0000-0003-1522-8860

Florian Rosar (F)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Elena Larsen (E)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Fadi Khreish (F)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Department of Nuclear Medicine, Klinikum Fulda gAG, Fulda, Germany.

Johannes Linxweiler (J)

Departments of Urology, Saarland University - Medical Center, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Robert J Marlowe (RJ)

Spencer-Fontayne Corporation, Jersey City, NJ, USA.
ORCID: 0000-0002-0943-2294

Andrea Schaefer-Schuler (A)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Stephan Maus (S)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Sven Petto (S)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Mark Bartholomä (M)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Samer Ezziddin (S)

Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Saarland University, USAAR, Saarbrücken, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Zirconium › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Dipeptides › Outstanding increase in tumor-to-background...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène spécifique de la prostate › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Produits chimiques inorganiques › Isotopes › Radio-isotopes › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Outstanding increase in tumor-to-background...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Outstanding increase in tumor-to-background...